965MO Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW

作者：Thomas Decaens, T. Yau, M. Kudo, B. Sangro, S. Qin, L. Da Fonseca, H. Karachiwala, Jung‐Won Park, E. Gane, Matthias Pinter, David Tai, Armando Santoro, Gonzalo Pizarro, C-F. Chiu, M. Schenker, A.R. He, Qi Wang, Takatsugu Ogata, Joseph Hreiki, Peter R. Galle · 发表于：Annals of Oncology · 年份：2024 · DOI：10.1016/j.annonc.2024.08.1025 · 被引用次数：11 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Liver physiology and pathology、Pancreatic and Hepatic Oncology Research